BidaskClub upgraded shares of Chimerix (NASDAQ:CMRX) from a hold rating to a buy rating in a report released on Friday morning.
A number of other research analysts have also recently weighed in on CMRX. ValuEngine cut shares of Chimerix from a sell rating to a strong sell rating in a report on Thursday, November 9th. Zacks Investment Research upgraded shares of Chimerix from a hold rating to a buy rating and set a $5.25 price target for the company in a report on Friday, November 10th. HC Wainwright assumed coverage on shares of Chimerix in a report on Friday, February 2nd. They set a buy rating and a $10.00 price target for the company. JPMorgan Chase & Co. cut shares of Chimerix from a neutral rating to an underweight rating in a report on Wednesday, February 14th. Finally, Cowen reiterated a hold rating and set a $6.00 price target on shares of Chimerix in a report on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Chimerix presently has a consensus rating of Hold and an average price target of $7.06.
Chimerix (NASDAQ:CMRX) opened at $5.69 on Friday. Chimerix has a twelve month low of $4.17 and a twelve month high of $6.64.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Voya Investment Management LLC grew its holdings in Chimerix by 18.3% during the 2nd quarter. Voya Investment Management LLC now owns 29,203 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 4,526 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in Chimerix during the 4th quarter worth approximately $137,000. The Manufacturers Life Insurance Company grew its holdings in Chimerix by 8.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 39,628 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 3,042 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Chimerix during the 4th quarter worth approximately $280,000. Finally, Nationwide Fund Advisors grew its holdings in Chimerix by 70.3% during the 3rd quarter. Nationwide Fund Advisors now owns 60,567 shares of the biopharmaceutical company’s stock worth $318,000 after acquiring an additional 24,994 shares in the last quarter. Institutional investors own 73.33% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Chimerix (CMRX) Upgraded to “Buy” by BidaskClub” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3257222/chimerix-cmrx-upgraded-to-buy-by-bidaskclub.html.
Chimerix Company Profile
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.